<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120106</url>
  </required_header>
  <id_info>
    <org_study_id>levoTGA1</org_study_id>
    <nct_id>NCT01120106</nct_id>
  </id_info>
  <brief_title>Levosimendan Administration in Neonates With Transposition of the Great Arteries</brief_title>
  <official_title>Perioperative Levosimendan Administration in Neonates With Transposition of the Great Arteries: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bambino Gesù Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bambino Gesù Hospital and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Calcium sensitizer drugs such as Levosimendan may exert anti-ischemic effect in addition to
      positive inotropic and anti-stunning effects mediated by the opening of ATP-sensitive
      potassium (KATP) channels. The aim of the study is to test the myocardial protection effect
      of peri-operative iv infusion of Levosimendan in a cohort of neonates affected by
      transposition of the great arteries undergoing surgical correction by arterial switch.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Function of the myocardium of neonates with congenital heart disease may be affected by
      several factors in post operative phase: congenital insufficiency, cardiopulmonary bypass low
      perfusion, ischemima during the cross-clamp phase, low cardiac output syndrome, systemic
      inflammation. Furthermore, neonates have immature molecular mechanisms leading to calcium
      utilization inside myocytes. Calcium sensitizer drugs such as Levosimendan may exert
      anti-ischemic effect in addition to positive inotropic and anti-stunning effects mediated by
      the opening of ATP-sensitive potassium (KATP) channels. The aim of the study is to test the
      inodilator and myocardial protection effect of peri-operative iv infusion of 0.1 mcg/kg/min
      Levosimendan (without previuos bolus) in a cohort of neonates affected by transposition of
      the great arteries undergoing surgical correction by arterial switch.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lower inotropic score in the levosimendan group</measure>
    <time_frame>Time points: from T0 (within 1 hour of intensive care unit admission) to T7 (72nd post operative hour) through T2, T3, T4, T5, T6, T7)</time_frame>
    <description>inotropic score will be calculated as: dopamine (mcg/Kg/min) * 1 + milrinone (mcg/Kg/min) * 15 + epinephrine (mcg/Kg/min) * 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Low cardiac output syndrome (LCOS) incidence reduction in the treatment group</measure>
    <time_frame>Time points: from T0 (within 1 hour of intensive care unit admission) to T7 (72nd post operative hour) through T2, T3, T4, T5, T6, T7)</time_frame>
    <description>LCOS will be estimated by the analysis of average heart rate, mean arterial pressure, left atrial pressure, lactates and pH during the evaluated time frame</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Low Cardiac Output Syndrome</condition>
  <arm_group>
    <arm_group_label>levosimendan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levosimendan continuous infusion at a rate of 0.1 mcg/kg&lt;min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levosimendan</intervention_name>
    <description>patients enrolled in this group will receive a levosimendan continuous infusion at a rate of 0.1 mcg/kg/min</description>
    <arm_group_label>levosimendan</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>simdax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>saline continuous infusion</description>
    <arm_group_label>levosimendan</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  neonates affected by transposition of the great arteries scheduled to elective surgery

        Exclusion Criteria:

          -  neonates affected by transposition of the great arteries who are not scheduled to
             elective surgery (urgent procedures, patients older than 30 days)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Picardo, MD, Head</last_name>
    <role>Study Director</role>
    <affiliation>Bambino Gesù Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bambino Gesù Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Di Chiara L, Ricci Z, Garisto C, Morelli S, Giorni C, Vitale V, Di Donato RM, Picardo S. Initial experience with levosimendan infusion for preoperative management of hypoplastic left heart syndrome. Pediatr Cardiol. 2010 Jan;31(1):166-7. doi: 10.1007/s00246-009-9571-6.</citation>
    <PMID>19915896</PMID>
  </reference>
  <reference>
    <citation>Osthaus WA, Boethig D, Winterhalter M, Huber D, Goerler H, Sasse M, Sümpelmann R. First experiences with intraoperative Levosimendan in pediatric cardiac surgery. Eur J Pediatr. 2009 Jun;168(6):735-40. doi: 10.1007/s00431-008-0834-7. Epub 2008 Sep 24.</citation>
    <PMID>18813947</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2010</study_first_posted>
  <last_update_submitted>June 22, 2012</last_update_submitted>
  <last_update_submitted_qc>June 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bambino Gesù Hospital and Research Institute</investigator_affiliation>
    <investigator_full_name>Zaccaria Ricci</investigator_full_name>
    <investigator_title>medical doctor</investigator_title>
  </responsible_party>
  <keyword>levosimendan</keyword>
  <keyword>pediatric cardiac surgery</keyword>
  <keyword>low cardiac output syndrome</keyword>
  <keyword>transposition of the great arteries</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiac Output, Low</mesh_term>
    <mesh_term>Transposition of Great Vessels</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

